Loncastuximab tesirine in previously treated WM

Recruiting
Written By Sustainable Digital

First trial using an ADC (antibody-drug conjugate) for WM in the world

Sites: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Mayo Clinic, Fred Hutchinson Cancer Center

Accrual status: 20 of 21 patients

Highlight: Oral presentation at ASH 2025

Sustainable Digital

Digital Communication services, including website design, search engine optimization, social media, and content creation for nonprofit organizations, consultants, and creative entrepreneurs.

http://www.sustainabledigital.com
Next

Zanubrutinib, Bendamustine, and Rituximab (ZEBRA) in previously untreated WM